Merck Shares Nosedive Following Vorapaxar Setback

Merck & Co., Inc. (MRK) announced today that clinical trials of its blood clot drug Vorapaxar will have to be altered, sending shares down more than 6%. Vorapaxar was once thought to be a potential multibillion-dollar blockbuster, and was a huge component of Merck’s merger with Schering-Plough Corp. But a Data and Safety Monitoring board [...]